a website banner telling users to subscribe to it's newsletter

Complement Therapeutics Enrolls First Patient in i-GAIN Study of People Diagnosed with GA

Complement Therapeutics Enrolls First Patient in i-GAIN Study of People Diagnosed with GA

February 10, 2023

Complement Therapeutics has made an announcement about the enrollment of the first participant in the i-GAIN study, a research project aimed at gaining insight into geographic atrophy (GA) - a condition that results in irreversible blindness and is caused by age-related macular degeneration (AMD).

The study, which will last for one year, will focus on individuals who have been diagnosed with GA in one or both eyes and will examine the connections between genetics, blood biomarkers, and changes in the eye. The results of the i-GAIN study will play a crucial role in the clinical development of CTx001, CTx's lead gene therapy asset, which is being developed to treat GA. The data will help in identifying and categorizing patients with complement-driven AMD, making it possible to conduct future intervention studies.

Dr Marta Ugarte, consultant ophthalmologist and principal investigator of the iGAIN study said “Today’s announcement is an important milestone in enabling researchers to gain a better understanding of this disease. We look forward to generating and analysing data from the i-GAIN study, which will provide insights into how the disease progresses.”

“A deeper understanding of the natural history of GA will provide important insights supporting the development of innovative medicines which can prevent vision loss in these patients,” said Dr Rafiq Hasan, Chief Executive Officer at Complement Therapeutics.

About the i-GAIN Study

The i-GAIN Study is a research project that aims to gather information about individuals over the age of 18 who have been diagnosed with geographic atrophy (GA). The study is designed as a multicentre, prospective natural history study and will take place across 12 sites in the United Kingdom, with an estimated enrolment of 250 patients.

Participants will not receive any experimental treatments or medications, as the i-GAIN Study is non-interventional in nature. Assessments will be conducted at the start of the study, and then at 6-month and 12-month intervals. If you are interested in enrolling in the i-GAIN Study, please send an email to iGAIN@complementtx.com for more information.